Related Experiment Video
Updated: Oct 6, 2025
10:26
Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology
Published on: August 18, 2014
26.4K
[SGLT2 inhibitors and RAAS blockers : similarities, differences and complementarity].
A J Scheen1, P Delanaye2,3
1Service de Diabétologie, Nutrition et Maladies métaboliques et Unité de Pharmacologie clinique, CHU Liège, Belgique.
Revue Medicale De Liege
|January 14, 2022
Summary
Renin-angiotensin-aldosterone system inhibitors (RAASi) and sodium-glucose cotransporter type 2 inhibitors (SGLT2i) both protect against heart failure and kidney disease progression. Combining these medications offers optimal cardiovascular and renal benefits with a good safety profile.
Area of Science:
- Pharmacology
- Cardiology
- Nephrology
- Diabetology
Background:
- Renin-angiotensin-aldosterone system inhibitors (RAASi) and sodium-glucose cotransporter type 2 inhibitors (SGLT2i) are crucial for managing cardiovascular and renal conditions.
- Both drug classes have demonstrated efficacy in patients with and without type 2 diabetes.
Purpose of the Study:
- To compare and contrast RAASi and SGLT2i medications.
- To highlight the benefits of combining RAASi and SGLT2i for improved patient outcomes.
Main Methods:
- Review of current pharmacological guidelines and clinical trial data.
- Comparative analysis of RAASi and SGLT2i mechanisms, efficacy, and safety profiles.
Main Results:
- Both RAASi and SGLT2i significantly reduce risks of heart failure and end-stage renal disease.
- Evidence supports the use of these agents across diverse patient populations, including those with and without type 2 diabetes.
- Combined therapy shows potential for enhanced cardiovascular and renal protection.
Conclusions:
- RAASi and SGLT2i are foundational therapies in diabetology, cardiology, and nephrology.
- Combining RAASi and SGLT2i is recommended for optimizing cardiovascular and renal prognosis.
- This combination approach maintains a favorable safety profile.
Related Concept Videos
01:25Antihypertensive Drugs: Direct Renin Inhibitors
881
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
881
01:24Glucagon-like Receptor Agonists
462
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
462
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
551
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
551
01:23Dipeptidyl Peptidase 4 Inhibitors
280
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
280
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
306
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
306
01:06Oral Hypoglycemic Agents: Glinides
291
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
291